2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-111038
    Capsiconiate 946572-73-2 98%
    Capsiconiate (Coniferyl (E)-8-methyl-6-nonenoate) is a TRPV1 agonist (EC50= 3.2 μM). Capsiconiate can be used to study TRPV1-mediated diseases such as pain, inflammation, and epilepsy(EC50= 3.2 μM).
    Capsiconiate
  • HY-111051
    JN403 942606-12-4 98%
    JN403 is an orally active and selective α7 nicotinic acetylcholine receptor agonist. JN403 can be used in the study of central nervous system disorders.
    JN403
  • HY-111093
    Protein kinase inhibitor 8 926319-75-7 98%
    Protein kinase inhibitor 8 (Compound CK59) is a calmodulin-dependent protein kinase II (CaMKII) inhibitor. By inhibiting the activity of CaMKII, Protein kinase inhibitor 8 can attenuate the cytotoxicity induced by perfluorooctane sulfonic acid (PFOS) and alleviate the downregulation of GLT-1 expression caused by PFOS, thereby reducing neuronal damage. Protein kinase inhibitor 8 may be useful in research related to neurodegenerative diseases.
    Protein kinase inhibitor 8
  • HY-111124
    Paroxetine-d2 923932-43-8 98%
    Paroxetine-d2 (CTP 347) is a deuterium labeled Paroxetine (HY-122272). Paroxetine is an oral inhibitor that falls under the category of selective serotonin reuptake inhibitors (SSRIs). Paroxetine is also a very weak norepinephrine (NE) reuptake inhibitor, capable of inducing cell apoptosis and having anti-tumor activity. Paroxetine has antidepressant, anti-anxiety, and pain-relieving effects, and it can help improve conditions like obsessive-compulsive disorder, panic disorder, post-traumatic stress disorder, premenstrual anxiety, and chronic headaches.
    Paroxetine-d2
  • HY-111155
    RBI-257 maleate 911378-38-6 98%
    RBI-257 maleate is a potent dopamine D4 receptor antagonist with a Ki value of 0.3 nM.
    RBI-257 maleate
  • HY-111157
    Dezinamide 91077-32-6 98%
    Dezinamide (ADD94057) is an antiepileptic agent. Dezinamide binds to the voltage-sensitive sodium channel.
    Dezinamide
  • HY-111189
    GSK931145 896117-64-9 98%
    GSK931145 is a glycine transporter 1 (GlyT1) inhibitor with anti-epileptic activity. GSK931145 exhibits a low minimum effective dose in the maximum electrical stimulation threshold test, indicating that it has a significant anti-epileptic effect. GSK931145 is also suitable as a positron emission tomography (PET) radioligand for quantifying the availability of glycine transporters in the living brain.
    GSK931145
  • HY-111197
    LY-2300559 889116-06-7 98%
    LY-2300559 is a low-solubility carboxylic acid (pKa = 4.5). LY-2300559 can be used for the research of migraine.
    LY-2300559
  • HY-111218
    TRPV1 antagonist 5 878811-00-8 98%
    TRPV1 antagonist 5 (compound 1) is a potent TRPV1 antagonist.
    TRPV1 antagonist 5
  • HY-111239
    GSK317354A 874119-13-8 98%
    GSK317354A is a ROCK and GRK inhibitor. GSK317354A can be used for heart failure and Parkinson’s disease research.
    GSK317354A
  • HY-111241
    SV 293 873445-73-9 98%
    SV 293 is a selective antagonist with neutral antagonist activity. SV 293 binds to human D2 receptors with 100-fold higher affinity and has lower affinity for human D3 and D4 dopamine receptor subtypes. SV 293 was found to block the effects of the full agonist quinpirole in forskolin-dependent adenylate acylase inhibition assays and electrophysiological assays. SV 293 can be used as a useful pharmacological tool to study the role of dopamine D2-like receptor subtypes in dopamine pathways associated with neurological, neuropsychiatric and movement disorders.
    SV 293
  • HY-111242
    SV 156 873445-60-4 98%
    SV 156 is a potent and selective D2 dopamine receptor antagonist, with a Ki of 2.5 nM for hD2. SV 156 has approximately 40-fold binding selectivity for D2 dopamine receptors compared to the D3 receptor subtype. SV 156 can be used for L-DOPA (HY-N0304)-associated abnormal involuntary movements (AIMs) research.
    SV 156
  • HY-111245
    AZD-1305 872045-91-5 98%
    AZD-1305 is an antiarrhythmic agent and atrial selective sodium channel/potassium channel blocker, which can significantly prolongs action potential duration and reduces excitability, cause atrial selective ERP prolongation and acute termination of atrial fibrillation. AZD1305 can be used for atrial fibrillation research.
    AZD-1305
  • HY-111258
    GSK345931A 869499-38-7 98%
    GSK345931A is an EP1 receptor antagonist. GSK345931A shows measurable CNS penetration in the mouse and rat and potent analgesic efficacy in acute and sub-chronic models of inflammatory pain.
    GSK345931A
  • HY-111280
    ST 198 854924-64-4 98%
    ST 198 is an orally active D3R antagonist. ST 198 can block the expression of nicotine-induced CPP at doses selective for D3R. ST 198 can be used for the research of neurological disease.
    ST 198
  • HY-111283
    AJ-76 85379-09-5 98%
    AJ-76 ((+)-AJ 76; (1S,2R)-AJ 76) is a dopamine autoreceptor antagonist. AJ-76 can increase the synthesis and turnover of dopamine in the rat brain, while having little effect on the synthesis and turnover of serotonin (5-HT) and norepinephrine. AJ-76 can also antagonize the sedative effects of low-dose apomorphine and has a weak antagonistic effect on postsynaptic dopamine receptor.
    AJ-76
  • HY-111298
    TG 41 850339-33-2 98%
    TG 41 is positive modulator of GABAA receptor. TG 41 enhances the binding both of GABA and of Flunitrazepam to rat cerebral cortical membranes.
    TG 41
  • HY-111367
    MS2734 2587612-25-5 98%
    MS2734 is a inhibitor of nicotinamide N-methyltransferase (NNMT). MS2734 potently inhibits the methyltransferase activity of human NNMT (hNNMT) with an IC50 value of 14 μM. MS2734 can be used for the study of obesity, diabetes, Parkinson's disease, and various cancers with high NNMT expression.
    MS2734
  • HY-111477
    (E/Z)-Ensifentrine 298680-25-8 98%
    (E/Z)-Ensifentrine is a dual inhibitor of PDE3/4. (E/Z)-Ensifentrine reduces the inflammatory cells into the airways. (E/Z)-Ensifentrine has bronchodilatory and anti-inflammatory activities in vitro and in vivo model.
    (E/Z)-Ensifentrine
  • HY-111480
    Propionylpromazine 3568-24-9 98%
    Propionylpromazine is a dopamine receptor DRD2 antagonist. Propionylpromazine also is an effective tranquillizer. Propionylpromazine can be used in veterinary studies.
    Propionylpromazine
Cat. No. Product Name / Synonyms Application Reactivity